These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 31343836)
1. Physiologically-Based Pharmacokinetic Modeling vs. Allometric Scaling for the Prediction of Infliximab Pharmacokinetics in Pediatric Patients. Malik PRV; Edginton AN CPT Pharmacometrics Syst Pharmacol; 2019 Nov; 8(11):835-844. PubMed ID: 31343836 [TBL] [Abstract][Full Text] [Related]
2. Prediction of Clearance and Dose of Midazolam in Preterm and Term Neonates: A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling. Mansoor N; Ahmad T; Alam Khan R; Sharib SM; Mahmood I Am J Ther; 2019; 26(1):e32-e37. PubMed ID: 27574923 [TBL] [Abstract][Full Text] [Related]
3. Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children. Centanni M; Zaher O; Elhad D; Karlsson MO; Friberg LE Cancer Chemother Pharmacol; 2024 Aug; 94(2):297-310. PubMed ID: 38782791 [TBL] [Abstract][Full Text] [Related]
4. A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling for the Prediction of Drug Clearance From Neonates to Adolescents. Mahmood I; Tegenge MA J Clin Pharmacol; 2019 Feb; 59(2):189-197. PubMed ID: 30192373 [TBL] [Abstract][Full Text] [Related]
5. The integration of allometry and virtual populations to predict clearance and clearance variability in pediatric populations over the age of 6 years. Edginton AN; Shah B; Sevestre M; Momper JD Clin Pharmacokinet; 2013 Aug; 52(8):693-703. PubMed ID: 23588537 [TBL] [Abstract][Full Text] [Related]
7. Model qualification of the PK-Sim® pediatric module for pediatric exposure assessment of CYP450 metabolized compounds. Yun YE; Edginton AN J Toxicol Environ Health A; 2019; 82(14):789-814. PubMed ID: 31405354 [TBL] [Abstract][Full Text] [Related]
8. Physiologically Based Pharmacokinetic Modeling of Oxycodone in Children to Support Pediatric Dosing Optimization. Zheng L; Xu M; Tang SW; Song HX; Jiang XH; Wang L Pharm Res; 2019 Oct; 36(12):171. PubMed ID: 31654287 [TBL] [Abstract][Full Text] [Related]
9. Physiologically Based Pharmacokinetic Modeling and Allometric Scaling in Pediatric Drug Development: Where Do We Draw the Line? Johnson TN; Ke AB J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S83-S93. PubMed ID: 34185901 [TBL] [Abstract][Full Text] [Related]
10. Prediction of Clearance in Neonates and Infants (≤ 3 Months of Age) for Drugs That Are Glucuronidated: A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling. Mahmood I; Ahmad T; Mansoor N; Sharib SM J Clin Pharmacol; 2017 Apr; 57(4):476-483. PubMed ID: 27704554 [TBL] [Abstract][Full Text] [Related]
11. PBPK and its Virtual Populations: the Impact of Physiology on Pediatric Pharmacokinetic Predictions of Tramadol. T'jollyn H; Vermeulen A; Van Bocxlaer J AAPS J; 2018 Nov; 21(1):8. PubMed ID: 30498862 [TBL] [Abstract][Full Text] [Related]
12. Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Pediatric Populations Using PK-Sim. Basu S; Lien YTK; Vozmediano V; Schlender JF; Eissing T; Schmidt S; Niederalt C Front Pharmacol; 2020; 11():868. PubMed ID: 32595502 [TBL] [Abstract][Full Text] [Related]
13. Model-Aided Adults-to-Children Pharmacokinetic Extrapolation and Empirical Body Size-Based Dosing Exploration for Therapeutic Monoclonal Antibodies-Is Allometry a Reasonable Choice? Xu Y; Langevin BA; Zhou H; Xu Z J Clin Pharmacol; 2020 Dec; 60(12):1573-1584. PubMed ID: 32578225 [TBL] [Abstract][Full Text] [Related]
14. Physiologically-Based Pharmacokinetic (PBPK) Modeling Providing Insights into Fentanyl Pharmacokinetics in Adults and Pediatric Patients. Kovar L; Weber A; Zemlin M; Kohl Y; Bals R; Meibohm B; Selzer D; Lehr T Pharmaceutics; 2020 Sep; 12(10):. PubMed ID: 32977559 [TBL] [Abstract][Full Text] [Related]
15. Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drug. Khalil F; Läer S AAPS J; 2014 Mar; 16(2):226-39. PubMed ID: 24399240 [TBL] [Abstract][Full Text] [Related]
16. Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model. Yamazaki S; Skaptason J; Romero D; Vekich S; Jones HM; Tan W; Wilner KD; Koudriakova T Drug Metab Dispos; 2011 Mar; 39(3):383-93. PubMed ID: 21098644 [TBL] [Abstract][Full Text] [Related]
17. DallphinAtoM: Physiologically based pharmacokinetics software predicting human PK parameters based on physicochemical properties, in vitro and animal in vivo data. Choi S; Han S; Lee SJ; Lim B; Bae SH; Han S; Yim DS Comput Methods Programs Biomed; 2022 Apr; 216():106662. PubMed ID: 35151112 [TBL] [Abstract][Full Text] [Related]
18. An Update on the Use of Allometric and Other Scaling Methods to Scale Drug Clearance in Children: Towards Decision Tables. van Rongen A; Krekels EH; Calvier EA; de Wildt SN; Vermeulen A; Knibbe CA Expert Opin Drug Metab Toxicol; 2022 Feb; 18(2):99-113. PubMed ID: 35018879 [TBL] [Abstract][Full Text] [Related]
19. Allometry Is a Reasonable Choice in Pediatric Drug Development. Liu T; Ghafoori P; Gobburu JV J Clin Pharmacol; 2017 Apr; 57(4):469-475. PubMed ID: 27649629 [TBL] [Abstract][Full Text] [Related]
20. Development and Application of a Physiologically-Based Pharmacokinetic Model to Predict the Pharmacokinetics of Therapeutic Proteins from Full-term Neonates to Adolescents. Pan X; Stader F; Abduljalil K; Gill KL; Johnson TN; Gardner I; Jamei M AAPS J; 2020 May; 22(4):76. PubMed ID: 32449129 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]